Abstract
Introduction
Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is a debilitating condition with poor survival prognosis. High resolution computed tomography (CT) is a common clinical tool to diagnose RA-ILD, and is increasingly being adopted in pre-clinical studies. However, murine models recapitulating RA-ILD are lacking, and CT outcomes for inflammatory lung disease have yet to be formally validated. To address this, we validate μCT outcomes for ILD in the tumor necrosis factor transgenic (TNF-Tg) mouse model of RA.
Methods
Cross sectional μCT was performed on cohorts of male TNF-Tg mice and their WT littermates at 3, 4, 5.5 and 12 months of age (n = 4–6). Lung μCT outcomes measures were determined by segmentation of the μCT datasets to generate Aerated and Tissue volumes. After each scan, lungs were obtained for histopathology and 3 sections stained with hematoxylin and eosin. Automated histomorphometry was performed to quantify the tissue area (nuclei, cytoplasm, and extracellular matrix) and aerated area (white space) within the tissue sections. Spearman’s correlation coefficients were used to evaluate the extent of association between μCT imaging and histopathology endpoints.
Results
TNF-Tg mice had significantly greater tissue volume, total lung volume and mean intensity at all timepoints compared to age matched WT littermates. Histomorphometry also demonstrated a significant increase in tissue area at 3, 4, and 5.5 months of age in TNF-Tg mice. Lung tissue volume was correlated with lung tissue area (ρ = 0.81, p<0.0001), and normalize lung aerated volume was correlated with normalized lung air area (ρ = 0.73, p<0.0001).
Conclusions
We have validated in vivo μCT as a quantitative biomarker of ILD in mice. Further, development of longitudinal measures is critical for dissecting pathologic progression of ILD, and μCT is a useful non-invasive method to study lung inflammation in the TNF-Tg mouse model.
Introduction
Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is a severe inflammatory condition that develops in 8–15% of all RA patients, and has a median survival expectancy of 2.6 years once diagnosed [1, 2]. RA-ILD has several subtypes including usual interstitial pneumonitis (UIP), non-specific interstitial pneumonitis (NSIP), lymphocytic interstitial pneumonitis (LIP), and desquamative interstitial pneumonitis (DIP). These subtypes can be generally classified into two major categories, fibrotic (UIP and fibrotic NSIP) and cellular based (cellular NSIP, LIP and DIP)[3, 4].
Clinical diagnosis and assessment of RA-ILD typically relies on the use of high resolution computed tomography (HRCT). This imaging modality permits determination of disease severity and progression over time in the clinic, and similar development of in vivo imaging modalities is essential for studying pathogenesis of RA-ILD in animal models. Just as HRCT has become the standard of care for imaging the lung in the clinic over the last decade[5], CT technologies have been adopted for small animal lung disease models[6, 7]. Despite recent advances however, the lung CT literature is limited to a few disease models, primarily used for assessment of cancer models or fibrotic lung disease, not an inflammatory cell driven lung diseases[6, 8].
The tumor necrosis factor transgenic (TNF-Tg) mouse is a well-established model of RA[9, 10]. Recently, investigators have shown that TNF-Tg mice develop a lymphocytic lung disease with significant infiltrates in the perivascular and peribronchiolar space [11–13]. However, course of disease and therapeutic intervention studies in this model have yet to be performed, largely due to the absence of validated in vivo longitudinal outcome measures. To address this major limitation in the field, we aimed to adopt the in vivo μCT method developed for bleomycin induced lung fibrosis[14] to assess the RA-ILD pathology in TNF-Tg mice, and to subsequently validate the μCT outcome measure with histomorphometry. We found a strong correlation between the lung tissue volume measured by μCT and histologic tissue area as well as between lung aerated volume measured by μCT, and lung air area determined by histomorphometry. Thus, μCT imaging can be utilized with confidence as a quantitative longitudinal biomarker of ILD in mice.
Materials and methods
Animals
The University of Rochester Medical Center University Committee on Animal Resources (UCAR) has approved of all animal work conducted herein. Anesthesia and Euthanasia were performed in accordance with our approved protocol. Briefly, 1.5–3% Isoflurane was used to anesthetize for all in vivo procedures and 300–360 mg/kg + xylazine 30–40 mg/kg IP was used to overdose the mice followed by cervical dislocation. The 3647 line of the TNF-Tg mouse was obtained originally from Dr. George Kollias[10, 15], and mice were compared to their non-transgenic wildtype (WT) littermates on a C57BL/6 background. Male mice at 3, 4, 5.5 and 12 months of age were imaged and sacrificed for histology (n = 4–6, number of replicates shown on each graph).
Micro-CT imaging procedure and analysis
Mice were anesthetized with 1.5% isoflurane and inserted prone into the imaging tube of a vivaCT 40 μCT (Scanco Medical, Brüttisellen, Switzerland). A pressure pad pillow (RX110, Biopac Systems) was placed underneath the abdomen of the animal and attached to a blood pressure transducer (BPS-BTA and SDAQ, Vernier, Beaverton OR) to detect movement of the chest to gate the μCT imaging to the expiratory pause in breathing. We developed a nonpredictive LabVIEW program (National Instruments, Austin, Texas, USA) that reliably detected the respiratory cycle, and used it to inhibit scanning underway. The μCT scanning parameters were: 1000 projections over 180°, 300 milliseconds integration time, 45 kVp, and 176 micro-amp current. DICOMs at 35 μm3 isotropic voxel resolution were imported to Amira (FEI, Hillsboro, Oregon, USA) for semi-automated segmentation, assuming that the lung is a smooth, non-porous organ primarily composed of less dense tissue. The “magic wand” tool, a threshold-based voxel connectivity tool, was used with thresholds of -1000 to -150 and an initial seed point in the bronchus was selected. The growing, shrinking, fill holes and smoothing tools were then used to segment the lung from the rest of the abdomen (Fig 1A–1C). To eliminate the conducting airways from the segmentation, the airways were manually segmented, and measured for diameter and a size exclusion on airways >200 μm was performed (Fig 1C). The intensity of each voxel in Hounsfield Units was then extracted to generate an intensity histogram (Fig 1D) used for all subsequent analyses. The weighted average density was calculated for each lung from the following formula, , where is the weighted mean,w is the weight (ie. frequency of the histogram bin), xi is the Hounsfield unit corresponding to the bin, and n is the number of bins (n = 2001, or -1000 HU to 1000 HU). Bin width has been set to 1 HU. A threshold of -256 HU was derived from the weighted averaged lung intensity of all WT mice in order to differentiate aerated lung and tissue lung volume, (Fig 1E). This threshold value represents the density of the interface between the alveolar epithelium and air in the alveoli, given that this interface is the largest volume in the lung, and is similar to the threshold value previously established for the lung[14]. Once the threshold was set, area under the curve was determined for each partition to obtain three outcome measures: total volume, tissue volume, and aerated volume. Tissue and aerated volumes were divided by the total volume to obtained normalized values, as a measure of how each outcome changes within the context of the organ as a whole. To correlate the μCT with the histologic outcomes, the left and right lungs were separated by anatomic features, and the left lung was used for all correlations (* and # in Fig 1A–1C).
The weighted computed tomography dose index (CTDIw) was calculated from the following equations, CTDIw = 1/3* CTDI center + 2/3*CTDI peripheral, where CTDI center is the CTDI at the center of the stage and CTDI peripheral is the CTDI around the periphery of the stage. The CTDI was calculated from the following equation , where N is the number of slices, T is the nominal section thickness, and D(z) is the radiation dose measured at the z position. The measured dosage is provided for a given imaging energy. Time, current, product and resolution is provided by Scanco. For scans <40mins at the imaging parameters we used the total dosage is <0.15 Gy. The gating procedure for the vivaCT 40 closes a shutter when gating is on to ensure termination of the beam.
Histology procedures and analysis
At sacrifice, the animals were dissected to expose the thoracic cavity and trachea. A 4–0 silk suture was loosely tied around the trachea and a 10ml syringe fitted with a 25-gauge needle filled with 10% neutral buffered formalin (NBF) was inserted into the trachea. Forceps were used to clamp the needle inside the lumen of the trachea to prevent backflow and instillation of NBF at >20mm H2O was performed until there was visual confirmation that all lobes of the lung were fully inflated, at which time the suture was tied tight and the lungs were excised[16, 17]. Then the left lung of each mouse was incubated in 10% formalin for 3 days, processed, embedded in paraffin and sectioned. The lung was sectioned from the dorsal aspect to the ventral aspect in a coronal manner. Three 5 μm thick sections were taken at least 200 μm apart, stained with hematoxylin and eosin, and whole slides were scanned (VS120, Olympus, Tokyo, Japan). These slide scanned images were analyzed with Visiopharm imaging software if there was a minimum of 15 μm2 of total lung area (Hoersholm, Demark). A region of interest (ROI) was drawn around the margin of the lung (Fig 2A) and a custom application was developed to detect the colorimetric differences between the shades of blue stain, red/pink stain and the background (white color). These colors were then classified into 3 categories (Blue, Pink, and White) to delineate the difference between the cell nuclei (Blue), cytoplasm, extracellular matrix and red blood cells (Pink) and alveolar space (White, Fig 2B–2E). Because red blood cells are often removed from major arteries during histologic processing, empty arteries were manually reclassified from “white” to “pink” (# in Fig 2D and 2E). These categories were used as independent outcomes, and the blue and pink categories were summated to obtain total lung tissue area. To minimized confounding effects of tissue processing that may decrease soft tissue volume, all histomorphometric categories were also normalized to the total area of the ROI within each slide.
Statistical analysis
All statistical tests were performed in JMP Pro 13 (SAS, Durham, NC). Data were assed for normality with Shapiro-Wilks tests and data were typically not normally distributed; therefore, normality was restored by rank transformation. Two-way ANOVAs were performed to examine the overall effect of genotype and age with Tukey’s post-hoc for multiple comparisons. When main effects were only observed for genotype, post-hoc t-tests with Bonferroni corrections for multiple comparisons (α = 0.05÷4 = 0.0125) were performed within each timepoints. Spearman rank correlation coefficients were computed from the raw, un-transformed data to describe associations between μCT and histology measures.
Results
TNF-Tg mice have increased lung tissue volume via in vivo μCT
Three dimensional representative reconstructions clearly demonstrate that TNF-Tg mice have greater tissue volume than their WT littermates at every timepoint (Orange-Red in Fig 3A–3H). Tissue density histograms were shifted right and had larger maxima for TNF-Tg lungs compared to WT lungs at every timepoint (Fig 3I–3L). Quantifying the differences between these histograms demonstrates that the weighted average density, total volume and tissue volume were increased at all timepoints for the TNF-Tg lungs compared to their age matched WT counterparts (Fig 3M, 3N and 3P). While the aerated volume in TNF-Tg lungs was decreased at 3 months compared to WT, it recovered to WT levels at 4 months and was significantly different at 5.5 months compare to 3 months (Fig 3O).
TNF-Tg mice have increased lung tissue area via histomorphometry
Representative images of a 12-month WT mouse lung versus lungs from 3, 4, 5.5 and 12-month TNF-Tg mice showed remarkable accumulation of inflammatory cells in the TNF-Tg lungs (Fig 4A–4E). Moreover, we observed an increase in Blue area (Cells) at all timepoints compared to WT littermates, but did not find an increase in Pink area (ECM, Blood, Cytoplasm, ect) at 4, 5.5 or 12 months of age, indicating that the ILD in TNF-Tg mice is primarily inflammatory and not fibrotic (Fig 4H and 4I). When normalized to whole lung area, the percent White area (Air) was significantly decreased at 3, 4, and 5.5 months of age in the TNF-Tg mice (Fig 4K), while the percent Blue area (Cells) remained increased in TNF-Tg mice at all timepoints (Fig 4L).
Tissue volume via μCT and tissue area via histomorphometry are correlated
Spearman Rank correlation coefficients were computed to describe the association of μCT and histology outcome measures. Total volume by μCT and total area by histomorphometry were highly correlated (ρ = 0.56, p<0.0001, Fig 5A), as were tissue volume and total tissue area (Blue + Pink area) (ρ = 0.82, p<0.0001, Fig 5B), but not aerated volume and White area (ρ = 0.08, p = 0.57). However, when the normalized aerated volume and White area were compared, a significant correlation between these outcomes was found (ρ = 0.72, p<0.0001, Fig 5C). As expected, the correlation between the normalized tissue volume and Blue + Pink area was also significant (ρ = 0.73, p<0.0001, Fig 5D). When the genotypes were analyzed independently, total volume and area were not significantly associated with each other for either genotype (Fig 5A). However, tissue volume and tissue area were associated for TNF-Tg mice independent of their WT littermates (ρ = 0.50, p<0.05, Fig 5B). Both normalized outcomes were not associated independent of genotype (Fig 5C and 5D)
Discussion
Developing in vivo imaging in small animal disease models is a crucial step towards elucidating the etiology and developing effective interventions for conditions like RA-ILD. Thus, we used μCT methodology to quantify tissue volume, aerated volume and total volume of an inflammatory murine lung disease, and found significant correlations with histomorphometry outcome measures. Importantly, tissue volume and tissue area were highly correlated, suggesting that this μCT outcome measure can be used to assess cellular infiltrate, extracellular matrix deposition, and/or edema in vivo. Prior research has suggested use of similar methods to quantify μCT outcomes in other lung disease models including fibrotic lung disease, emphysema and fungal infections [6, 7, 14]. Our extension of this work with a mouse model of RA-ILD thus expands the utility of in vivo μCT for quantifying lung disease.
While TNF is known to induce pathologic changes in the lung [11, 13], the temporal lung pathology in TNF-Tg mice had not been previously characterized using μCT imaging, nor have histological studies of disease progression been reported. Thus, our finding of significant increases in Blue area (cells) without changes in Pink area confirm previous reports that TNF driven lung disease comprises a largely lymphocytic disease process, but in our model, does not progress to a fibrosing disease [11, 13]. In contrast to our findings, Bawadekar et al observed increased pathology within the lung over time, where as we did not find any temporal differences in lung tissue volume or tissue area with histomorphometry. This may be due to our 35 μm3 resolution limiting the ability to identify radiographic features more sensitive to change and that we did not further segment our histomorphometry to investigate specific compartments of the lung (e.g. peribronchiolar, perivascular, septal areas etc.). However, 35 μm3 is the highest in vivo resolution we can image at and further automated segmenting of histomorphometry was not possible with our methodology. The finding that our model does not progress to a fibrotic or emphysema-like phenotype contrasts with studies performed in mice overexpressing TNF driven from the surfactant protein C promoter (SP-C/TNF-Tg) restricting expression to the lung [11, 12, 18, 19]. These studies identified an initial lymphocytic alveolitis that progressed to a fibrotic and emphysema like phenotype with collagen deposition in the interstitium, over expanded lungs and enlargement of the alveoli [11, 19]. These structural changes are likely due to TNF induced aberrant expression of remodeling proteins, such as MMPs, TIMPs and CASPs [20]. Interestingly, Aerated volume was decreased at 3 months of age in our TNF-Tg mice compared to WT likely due to smaller aerated volume through post-natal development. This volume increased to WT levels at 4 months suggesting a protective compensation, in marked contrast to acute lung disease models, such as bleomycin induced lung fibrosis, that show an immediate loss of aerated volume with no compensatory recovery across 28 days [6, 7, 14]. However, this increase in aerated lung volume could also be pathologic resembling the emphysema-like phenotype in the SPC/TNF-Tg mice. Further studies investigating lung function and pathophysiology are needed to elucidate these differences between models.
Soft tissues are known to undergo deformation changes during histologic processing, and is an established limitation of histomorphometry. To address this, the American Thoracic Society and the European Respiratory Society have published guidelines regarding the treatment of lung tissue for various outcomes, to minimize histology artifacts between samples [21]. Two guidelines of importance are the instillation pressure and fixative used. Instillation pressure should be >20 mmH2O for proper inflation of the lung tissue. Fixatives recommended include either formaldehyde or glutaraldehyde; the former will ensure proper fine tissue fixation and preserve epitopes for immunohistochemistry (IHC) and the latter ensures a strong fixation to stabilize the gross architecture but limits accessibility to epitopes [21]. Due to the interest in further characterization of the lung disease and consistency in future studies in this mouse, we chose neutral buffered formaldehyde to preserve epitopes for IHC. This decision may lead to the potential for volumetric changes between samples and may be a possible reason for the lack of correlation between aerated lung volume and white area. However, the relative relationship between the two outcomes can be assessed by normalizing within each sample to the total volume or area to obtain the relative contribution of each sub-compartment (e.g. aerated volume, tissue volume, blue area, white area). This is demonstrated by the significant correlation of percent aerated volume to percent white area (Fig 5C).
The gold standard for histology outcome measures is to have an expert reader or certified pathologist characterize or categorize pathologic changes within the tissue of interest. While this accepted practice is beneficial, expert graders are susceptible to implicit and explicit bias. Furthermore, since the training and time required to become an expert grader is often prohibitive, automated histomorphometry is an attractive alternative. We therefore developed an automated histomorphometric method to analyze lung ROIs in a cost-effective and unbiased manner that correlated with in vivo μCT outcome measures. It should be noted that this method cannot yet assess specific pathologic findings directly, such as perivascular accumulation of infiltrating immune cells versus arteriolar hypertrophy.
When conducting experiments with ionizing radiation, dosage should be considered due to its known toxic effects, especially in the lungs. In this study, mice received one <40-minute scan calculated to be <0.15 Gy which is well below the known toxic amount of x-ray radiation. When used in longitudinal studies, total radiation exposure must be taken into account, but no adverse effects have been reported from multiple imaging sessions of 0.62 Gy x 13 sessions and 0.813 Gy x 4 sessions [14, 22].
The value used to threshold aerated volume from tissue volume is critically important, as these are the two primary outcomes. We used the weighted average of the WT lung densities to differentiate the two volumes, presuming that the most common density will be the interface between the alveolar epithelium and the air directly adjacent. De Langhe et al reported a threshold of -383 HU that was determined by visual inspection of “lung regions directly above the diaphragm” on μCT scans [14]. We investigated if the results of our study would change if this value was used instead, and all results and interpretations of the data are unchanged. Examination of the raw histograms suggests that many threshold values would confer the outcomes presented herein (Fig 3I and 3L and S1 File). Differences in this thresholding value are to be expected due to a variety of factors including different imaging parameters, μCT machines, or post acquisition processing. However, a unifying logical algorithm can be adopted for cross study comparisons.
One limitation of our μCT method is that the isotropic resolution of our scans (35 μm3) prevented evaluation of possibly clinically relevant morphologic features [5]. Higher resolution scans would minimize this issue, but would also significantly increase scan time by a factor of 2–3, thereby increasing radiation dosage and reducing throughput. Additionally, it is unclear whether improved visualization of radiologic characteristics would be informative given that the clinical trajectory is to move away from descriptive imaging and towards more objective parameters[23].
An additional limitation of our μCT method is that we used a semi-automated segmentation method with manual inspection of the whole lung segment that may introduce observer bias; this bias can be overcome using blinding techniques and attending to interobserver reliability measures. Other groups have developed custom automated algorithms to perform segmentation of the air space within lung but these algorithms do not segment the tissue volume[6]. The challenge for automated algorithms is the similarity in density of cellular accumulations within the lung compared to adjacent organs. This is primarily due to CT inability to provide high contrast between the densities of soft tissue, which can likely be overcome with use of a contrast agent.
In summary, we have determined and validated an imaging method for quantifying disease progression in an inflammatory lung model using an established mouse model of RA-ILD. This methodology using μCT to assess inflammatory lung disease progression correlates well with histological disease progression. Therefore, μCT is a useful and cost-effective method for biomarker quantification in longitudinal preclinical studies.
Supporting information
Acknowledgments
The authors would like to acknowledge Mike Thullen in the Biomechanics, Biomaterials, and Multimodal Tissue Imaging (BBMTI) Core at the University of Rochester Medical Center for his technical expertise performing the μCT scans. The authors would also like to acknowledge Kathy Maltby and Sarah Mack in the Histology, Biochemistry and Molecular Imaging Core at the University of Rochester Medical Center for their technical expertise with the histology performed herein. The authors would like to thank Dr. Christopher Beck in the Department of Biostatistics and Computational Biology for his expertise and consultation performing statistical methods presented here. Lastly, we would like to acknowledge Javier Rangel-Moreno in the Department of Medicine for his technical expertise collecting the lung tissue for histology.
Data Availability
All relevant data are within the paper and its Supporting Information files.
Funding Statement
This work was supported by the National Institute of Health: National Institute of Arthritis and Musculoskeletal and Skin, T32 AR053459 (https://www.niams.nih.gov/); National Institute of Health: National Institute of Arthritis and Musculoskeletal and Skin, P30 AR061307, EMS (https://www.niams.nih.gov/); National Institute of Health: National Institute of Arthritis and Musculoskeletal and Skin, K08 AR067885, HR (https://www.niams.nih.gov/); National Institute of Health: National Institute of Arthritis and Musculoskeletal and Skin, R01 AR56702 EMS (https://www.niams.nih.gov/); National Institute of Health: National Institute of Child Health and Human Development, HD068373-04 (https://www.nichd.nih.gov/Pages/index.aspx). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583–91. doi: 10.1002/art.27405 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Doyle JJ, Eliasson AH, Argyros GJ, Dennis GJ, Finger DR, Hurwitz KM, et al. Prevalence of pulmonary disorders in patients with newly diagnosed rheumatoid arthritis. Clin Rheumatol. 2000;19(3):217–21. [DOI] [PubMed] [Google Scholar]
- 3.Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322–8. doi: 10.1183/09031936.00092309 [DOI] [PubMed] [Google Scholar]
- 4.Shaw M, Collins BF, Ho LA, Raghu G. Rheumatoid arthritis-associated lung disease. Eur Respir Rev. 2015;24(135):1–16. doi: 10.1183/09059180.00008014 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824. doi: 10.1164/rccm.2009-040GL [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Vande Velde G, Poelmans J, De Langhe E, Hillen A, Vanoirbeek J, Himmelreich U, et al. Longitudinal micro-CT provides biomarkers of lung disease that can be used to assess the effect of therapy in preclinical mouse models, and reveal compensatory changes in lung volume. Dis Model Mech. 2016;9(1):91–8. doi: 10.1242/dmm.020321 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Rodt T, von Falck C, Dettmer S, Halter R, Maus R, Ask K, et al. Micro-computed tomography of pulmonary fibrosis in mice induced by adenoviral gene transfer of biologically active transforming growth factor-beta1. Respir Res. 2010;11:181 doi: 10.1186/1465-9921-11-181 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Clark DP, Badea CT. Micro-CT of rodents: state-of-the-art and future perspectives. Phys Med. 2014;30(6):619–34. doi: 10.1016/j.ejmp.2014.05.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10(13):4025–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Li P, Schwarz EM. The TNF-alpha transgenic mouse model of inflammatory arthritis. Springer Semin Immunopathol. 2003;25(1):19–33. doi: 10.1007/s00281-003-0125-3 [DOI] [PubMed] [Google Scholar]
- 11.Lundblad LK, Thompson-Figueroa J, Leclair T, Sullivan MJ, Poynter ME, Irvin CG, et al. Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype. Am J Respir Crit Care Med. 2005;171(12):1363–70. doi: 10.1164/rccm.200410-1349OC [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Miyazaki Y, Araki K, Vesin C, Garcia I, Kapanci Y, Whitsett JA, et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest. 1995;96(1):250–9. doi: 10.1172/JCI118029 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Bawadekar M, Gendron-Fitzpatrick A, Rebernick R, Shim D, Warner TF, Nicholas AP, et al. Tumor necrosis factor alpha, citrullination, and peptidylarginine deiminase 4 in lung and joint inflammation. Arthritis Res Ther. 2016;18(1):173 doi: 10.1186/s13075-016-1068-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.De Langhe E, Vande Velde G, Hostens J, Himmelreich U, Nemery B, Luyten FP, et al. Quantification of lung fibrosis and emphysema in mice using automated micro-computed tomography. PLoS One. 2012;7(8):e43123 doi: 10.1371/journal.pone.0043123 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Douni E, Akassoglou K, Alexopoulou L, Georgopoulos S, Haralambous S, Hill S, et al. Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. J Inflamm. 1995;47(1–2):27–38. [PubMed] [Google Scholar]
- 16.Slight SR, Rangel-Moreno J, Gopal R, Lin Y, Fallert Junecko BA, Mehra S, et al. CXCR5(+) T helper cells mediate protective immunity against tuberculosis. J Clin Invest. 2013;123(2):712–26. doi: 10.1172/JCI65728 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Kang DD, Lin Y, Moreno JR, Randall TD, Khader SA. Profiling early lung immune responses in the mouse model of tuberculosis. PloS one. 2011;6(1):e16161 doi: 10.1371/journal.pone.0016161 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Fujita M, Shannon JM, Irvin CG, Fagan KA, Cool C, Augustin A, et al. Overexpression of tumor necrosis factor-alpha produces an increase in lung volumes and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2001;280(1):L39–49. doi: 10.1152/ajplung.2001.280.1.L39 [DOI] [PubMed] [Google Scholar]
- 19.Fujita M, Ouchi H, Ikegame S, Harada E, Matsumoto T, Uchino J, et al. Critical role of tumor necrosis factor receptor 1 in the pathogenesis of pulmonary emphysema in mice. Int J Chron Obstruct Pulmon Dis. 2016;11:1705–12. doi: 10.2147/COPD.S108919 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Thomson EM, Williams A, Yauk CL, Vincent R. Overexpression of tumor necrosis factor-alpha in the lungs alters immune response, matrix remodeling, and repair and maintenance pathways. Am J Pathol. 2012;180(4):1413–30. doi: 10.1016/j.ajpath.2011.12.020 [DOI] [PubMed] [Google Scholar]
- 21.Hsia CC, Hyde DM, Ochs M, Weibel ER, Structure AEJTFoQAoL. An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med. 2010;181(4):394–418. doi: 10.1164/rccm.200809-1522ST [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Plathow C, Li M, Gong P, Zieher H, Kiessling F, Peschke P, et al. Computed tomography monitoring of radiation-induced lung fibrosis in mice. Invest Radiol. 2004;39(10):600–9. [DOI] [PubMed] [Google Scholar]
- 23.Gruden JF. CT in Idiopathic Pulmonary Fibrosis: Diagnosis and Beyond. AJR Am J Roentgenol. 2016;206(3):495–507. doi: 10.2214/AJR.15.15674 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All relevant data are within the paper and its Supporting Information files.